Managing anthracycline-induced cardiotoxicity: Beginning with the end in mind

Future Cardiology

Volumn 11, Issue 4, 2015, Pages 363-366

  Salvatorelli, Emanuela ^a   Menna, Pierantonio ^a   Minotti, Giorgio ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Anthracyclines; Cardiotoxicity; Comorbidities; Dexrazoxane; Doxorubicin; Heart failure; Prevention; Surveillance; Survivors

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC ANTIBIOTIC;

CARDIOTOXICITY; CONGESTIVE CARDIOMYOPATHY; DRUG SAFETY; HUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME; CHEMICALLY INDUCED; HEART DISEASES; NEOPLASMS;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTOXICITY; HEART DISEASES; HUMANS; NEOPLASMS;

EID: 84939442674     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/FCA.15.35     Document Type: Review

References (20)

1. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97(11), 2869-2879 (2003).
2. Minotti G, Salvatorelli E, Menna P. Pharmacological foundations of Cardio-Oncology. J. Pharmacol. Exp. Ther. 334(1), 2-8 (2010).
3. Swerdlow AJ, Higgins CD, Smith P et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: A collaborative British Cohort Study. J. Natl Cancer. Inst. 99(3), 206-214 (2007).
4. Yeh ET, Salvatorelli E, Menna P, Minotti G. What is cardiotoxicity? Progr. Pediatr. Cardiol. 36(1-2), 3-6 (2014).
5. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91(5), 710-717 (1979).
6. Salvatorelli E, Menna P, Cantalupo E et al. The concomitant management of cancer therapy and cardiac therapy. Biochim. Biophys. Acta doi: 10. 1016/j. bbamem. 2015. 01. 003 (2015) (Epub ahead of print).
7. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56(2), 185-229 (2004).
8. Lipshultz SE, Miller TL, Lipsitz SR et al. Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes. Pediatrics 130(6), 1003-1011 (2012).
9. Menna P, Gonzalez Paz O, Chello M et al. Anthracycline cardiotoxicity. Expert. Opin. Drug. Saf. 11(Suppl. 1), S21-S36 (2012).
10. Swain SM, Whaley FS, Gerber MC et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol. 15(4), 1318-1332 (1997).
11. Tebbi CK, London WB, Friedman D et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J. Clin. Oncol. 25(5), 493-500 (2007).
12. Lipshultz SE, Franco VI, Sallan SE et al. Dexrazoxane for reducing anthracyclinerelated cardiotoxicity in children with cancer: an update of the evidence. Progr. Pediatr. Cardiol. 36(1-2), 39-49 (2014).
13. Wouters KA, Kremer LC, Miller TL et al. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br. J. Haematol. 131(5), 561-578 (2005).
14. Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapyinduced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114(23), 2474-2481 (2006).
15. Minotti G. Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs. J. Pharmacol. Exp. Ther. 346(3), 343-349 (2013).
16. Vejpongsa P, Yeh ETH. Prevention of anthracycline-induced cardiotoxicity J. Am. Coll. Cardiol. 64(9), 938-945 (2014).
17. Menna P, Salvatorelli E, Minotti G. Cardiotoxicity of antitumor drugs. Chem. Res. Toxicol. 15(9), 1179-1189 (2008).
18. Nathan PC, Ford JS, Henderson TO et al. Health behaviors, medical care, and interventions to promote healthy living in the Childhood Cancer Survivor Study cohort. J. Clin. Oncol. 27(14), 2363-2373 (2009).
19. Jones SE, Holmes FA, O'Shaughnessy JA et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7 year follow-up of US Oncology Research Trial 9735. J. Clin. Oncol. 27(8), 1177-1183 (2009).
20. Gianni L, Valagussa P. Anthracyclines and early breast cancer: the end of an era? J. Clin. Oncol. 27(8), 1155-1157 (2009).